HUTCHMED Presents HMPL-A251 Preclinical Data At AACR-NCI-EORTC Showing Potent HER2-Targeted PI3K/PIKK Inhibitor With Robust Antitumor Activity And Low Toxicity
Benzinga Newsdesk 1 year ago
News
First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities Unique, highly potent PI3K/PIKK inhibitor payload
- First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities
- Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload —
- Preclinical data shows robust antitumor activity with synergistic and bystander killing effects